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Adopting a Fully Single-Use Process: A Leachables and Patient Safety Evaluation Case Study
Elizabeth Goodrich, Jessica Shea, Paul Killian, Paul Becket, Thomas Broschard

The implementation of single-use technologies for
pharmaceutical product development continues to gain
momentum; this trend is due to the advantages of increased
flexibility, speed of implementation and lower capital
investment. In particular, they are seen as a means to
accelerate the production of material for clinical trials.
However, a primary concern regarding the use of such
technologies is the level and impact of leachables in the final
drug substance. Typically this concern is addressed through
a risk assessment utilizing extractable substances data
based on model solvent extractions from individual
components and devices.
However, little if any data has been published where
leachables are evaluated under actual process conditions
through a complete single-use clinical-scale process train.
We have addressed this by completing a pilot scale 100 L
“mock” mAb production and purification where the cells, and
hence mAb protein, are absent but where the bioreactor was
run for the normal duration with cell culture media and feeds,
and the DSP train utilized all the standard process devices,
buffers, conditions, and procedures. Data will be presented
on the leachables profile throughout the entire production
process and, where relevant placed within the context of a
patient risk assessment.

E&L PDA Definitions
Extractables
“Any chemical component that is removed from a
material by the application of an artificial or exaggerated
force (e.g., solvent, temperature or time).”
Determined under “worst-case” conditions following
the Model Stream approach.
Leachables
“A chemical component that migrates from a contact
surface into a drug product or process fluid during
storage or normal use conditions.”

A Fully Single-use Mab Process

Patient Exposure to Leachables in BDS

t=0 Culture Fluid

Based on mAb low dosing regimen of 50 mg API/1 week

13-day
Culture
Fluid

Bioreactor
Mobius® 200 L
Bioreactor

Depth Filtration
Millistak+® D0HC +
X0HC Pod filters

Millipore
UF/DF
®
Express
Pellicon® 3 Ultracel
SHC filter
30kD cassette

Sample
Analysis
Methods
Sample
Analysis
Methods

Determined with the product under normal
processing/storage conditions.

Compliance with the regulations is achieved not by the
execution of a single discrete study or report, but rather by the
conduct of a step-wise and risk based process as outlined
below. The main steps of an evaluation are listed here. These
steps are a condensation of the process flow diagrams /
decisions trees that are advocated by groups like BPSA
(Bioprocess Systems Alliance) and PQRI (Packaging Quality
Research Institute).
• Build in quality by selecting well qualified and safe materials
assess overall risk of materials on product / patient
• Generate extractables information in model solvents under
worst-case conditions
• Patient safety risk assessment
• Conduct leachables studies as necessary
• Demonstrate non-toxicity
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Virus Inactivation
Mobius® Mix system with
Millipore
Express® SHC filter

Viresolve® Pro
solution

Membrane
adsorber

CEX Step
Fractogel® SO3
resin

Results






No inoculation
13 days at process temperature & agitation
Sampled at t=0, t=13 days
Day 13 harvest followed by full DSP






Full-scale operations with all devices/resins
All unit operations utilized single-use systems & flowpaths
All process buffers prepped & stored in SU bags
Sampling from each buffer bag/process intermediate pool

 GC-MS (VOC and sVOC)
 LC-MS (non VOC)
 ICP (Metals)

Unit
Operation

Devices

# Sterile
Filters

# System
Flowpaths

# Product
Bags

# Buffer
Bags

Bioreactor

n/a

1

1

1

2

Harvest

2.64 m2

2

2

1

2

Capture Chrom

1.6 L

5

3

5

8

CEX Chrom

1.6 L

2

2

1

6

AEX Chrom

50 mL

2

2

3

Virus Filtration

0.14 m2

2

2

1

3

TFF-UFDF

0.5 m2

1

2

1

4

BDS Filtration

0.029 m2

0

1

1

0

4

In the table presented we can gain an appreciation for the vast
amount and number of product contact materials that are included
in the Mab template and this process run. A number of sterile
filters, single-use bags, and flowpaths (tubing and connectors) are
associated with each unit operation comprising more than 150
components.

EMD Millipore and the M logo are registered trademarks of Merck KGaA, Darmstadt, Germany.
Mobius, Millistak+, Viresolve, Millipore Express, ProSep, Pellicon, Ultracel, Fractogel and Provantage are registered trademarks of Merck KGaA, Darmstadt, Germany. ® 2015 EMD Millipore Corporation, Billerica, MA, USA. All rights reserved.

Total Mass of Leachables through Process
250
200

Case Study: Assume BDS API concentration = 100 g/L
BDS LEA
Concentration
(µg/mL)

Dosage (mL)

Leachables Total
µg/dose

0.9

5.0

4.4

Based on mAb high dosing regimen of 1050 mg API/1 week

Post CEX
pool

Viral Filtration

Summary of Material Exposure

E&L Evaluation Process

Post VI
Pool

AEX Step

A simulated Mab process was executed using the process template
shown above. Samples were collected from each process
intermediate pool as indicated by the blue circles. Process fluids
were comprised of the standard cell culture media, feeds, and
buffers without the presence of cells or product protein. The
process utilized single-use materials during all primary unit
operations and ancillary operations such as media and buffer prep.
All process and ancillary filters were pre-flushed per user guide
instructions. The process was operated on a 5 day/10 hr. shift
basis during the downstream process (DSP). Most buffers and
product intermediate pools were stored overnight and in some
cases over the weekend; no attempt to was made to minimize hold
times by running 24-hour operations.

Downstream
Processing
Downstream Processing
100 gram scale

Post
Capture
Pool

Post
AEX pool

Study Methodology

200L SU Bioreactor
Fed Batch with Cell
Culture Media

Capture Step
ProSep® Ultra Plus
resin

Post
VF Pool

Bulk Drug
Substance
t=0 days
t=7 days

Clarified
Harvest
Pool

Total Mass of Leachables [mg]

Abstract

Note: 81L out of 150L of the day 13
Bioreactor fluid was carried into the DSP

150
100
50

Case Study: Assume BDS API concentration = 10 g/L
BDS LEA
Concentration
(µg/mL)
0.9

Dosage (mL)

Leachables Total
µg/dose

105.0

91.6

Need for Patient Safety Evaluation
 The concentration of total leachables would fall above a
worst-case threshold exposure limit of 1.5 ug/day based on
the >10 year TTC-based acceptable intake of a mutagenic
impurity
 Toxicity of individual compounds need to be further
evaluated to demonstrate the concentrations are below
safety thresholds

A Look at Individual compounds

0

 Results did not indicate an accumulation of Leachables
through the process
 No compounds identified indicated a toxicological concern
Summary of Bioreactor Samples
Day 0
 <0.1 ppm in total VOC
leachables. These compounds
include: alkanes, aldehydes,
ketones.
 0.95 ppm in total SVOC
leachables. These compounds
include: branched alkenes, long
chain alcohols, ketones, and
siloxanes.
 ICP and LCMS did not observe
any compounds except those
which are part of the media
formulation.

Day 13

 0.22 ppm in total VOC leachables.
These compounds include:
alkanes, aldehydes, ketones.
 1.34 ppm in total SVOC
leachables. These compounds
include: branched alkenes, long
chain alcohols, aldehydes, and
siloxanes.
 ICP did not observe any
compounds except those which are
part of the media formulation.
 Trace amount (<20 ppb) of bis-ditert-butyl phenol phosphate (bisDtBPP).

Summary of Bulk Drug Substance Samples
Day 0
Day 7
 <0.1 ppm in total VOC leachables.  0.21 ppm in total VOC leachables.
The compounds include: alkanes, The compounds include: alkanes,
aldehydes, ketones.
aldehydes, ketones.
 0.38 ppm in total SVOC
 0.67 ppm in total SVOC
leachables. The compounds
leachables. The compounds
include: branched alkenes, long
include: branched alkenes, long
chain alcohols, siloxanes and 2,4- chain alcohols, siloxanes and 2,4di-tert-butylphenol.
di-tert-butylphenol.
 ICP and LCMS did not observe
 ICP and LCMS did not observe
any compounds.
any compounds.

Leachables
Compound Conc
(µg/mL)

Dosage
(mL)

Leachable
Compound
µg/dose

Permissible Daily
Exposure (PDE) Limit
µg/day

0.11

105.0

11.6

3750

 The leached compound identified in the greatest
concentration within the BDS after 7 days storage was
Hexanal (CAS 66-25-1)
 Hexanal is a VOC identified and quantified via HS GCMS at
a concentration of 110 ppb or 0.11 ppm
 Ex. A PDE for Butanal/Pentanal was established at 3.75
mg/person/day

Conclusion
 Complete Leachables Blank Run demonstrates that the
downstream purification unit operations provide a level of
removal of leachables throughout the process
 Study confirms and supports direction of industry to focus
on evaluating E&L from the bioreactor and from BDS
storage through to drug product
 Study brings confidence in patient safety in regard to
leachables from single-use processes as demonstrated by
evaluating patient safety thresholds
 Final filling operations utilize primarily the same MoC’s as
evaluated here, providing confidence that leachables
should not pose a safety hazard
 Provides confidence that leachates from the Provantage®
ClinicReady template will not adversely impact the clinical
studies vs. a traditional process and that the
materials/media contained within the Provantage®
ClinicReady template are commercially viable from a
material safety standpoint
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